Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://www.accesswire.com/703518/Manhattan-BioSolutions-Enters-into-a-Research-Collaboration-And-License-Option-Agreement-with-Binghamton-University-for-the-New-Linker-Payload-Technology NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic […]

New York City, New York Feb 23, 2021 (Issuewire.com)  – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies […]

New York City, New York Jun 29, 2021 (Issuewire.com)  – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]

NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the […]